Medication info
Sitdime Met Extended-Release Tablet 100/1000 mg

Sitdime Met Extended-Release Tablet 100/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Donghwa Pharmaceutical Co., Ltd.
Appearance
Bright blue, oval-shaped extended-release film-coated tablets with a convex surface on both sides.
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201899 · Approved 2022.05.10 · Insurance code 642707300

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin treatment: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily with their current metformin regimen may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is a total daily dose of sitagliptin 100 mg; the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1,000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Donghwa Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes when combined with diet and exercise. It effectively improves patients' blood glucose levels and supports blood sugar regulation. These treatment methods can strengthen blood glucose management and contribute to the prevention of complications associated with diabetes. Therefore, this medication plays an important role in the control of blood glucose in type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin treatment: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily with their current metformin regimen may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is a total daily dose of sitagliptin 100 mg; the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1,000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication contains sitagliptin and metformin and is used in diabetes treatment. Firstly, an allergic reaction may occur when taking this medication; thus, if symptoms such as rash, urticaria, or difficulty breathing appear, the patient should discontinue use immediately and consult a doctor. Additionally, severe side effects such as acute pancreatitis characterized by inflammation of the pancreas have been reported, so if abdominal pain, vomiting, or severe dyspeptic symptoms occur during use, careful observation is necessary, and the medical staff should be notified immediately. This medication should not be administered to patients with poor kidney function, and regular renal function tests should be conducted if kidney function declines. Patients with severe renal impairment, heart failure, acute infection, dehydration, or acute myocardial infarction should not take this medication. Furthermore, the administration of this medication should be suspended before and after tests that use radiographic iodine contrast agents, and it may be resumed once normal kidney function is confirmed. Women who are pregnant or may become pregnant, women who are breastfeeding, and children under the age of 18 are advised not to use this medication. This medication carries a risk of hypoglycemia, so especially when taken with insulin or sulfonylureas, blood sugar changes should be closely monitored, and appropriate action should be taken immediately if hypoglycemic symptoms occur. It is recommended to avoid alcohol consumption during treatment, and if sudden dehydration, vomiting, diarrhea, or other symptoms occur, the use of this medication should be temporarily suspended, and the patient should consult a doctor. If a surgery is planned, this medication should be stopped 48 hours before surgery and restarted only after confirming that kidney function has returned to normal post-surgery. Rarely, vitamin B12 levels may decrease, so it is advisable to conduct regular blood tests to check the vitamin B12 status for long-term users. If any abnormal symptoms or discomfort persists during treatment, the patient should consult a medical professional immediately.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 18 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • rash
  • urticaria
  • cutaneous vasculitis
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius to preserve the medication's effectiveness and safety over time.

Appearance and packaging

Appearance

Bright blue, oval-shaped extended-release film-coated tablets with a convex surface on both sides.

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.